Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

54.84 +0.56 (+1.03%)
Streaming Delayed Price Updated: 3:55 PM EST, Jan 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
34 35 Next >
News headline image
Genentech Announces Positive Data from Broad Blood Cancer Portfolio at European Hematology Association Annual Meeting
From Genentech
Via Business Wire
News headline image
The Daily Biotech Pulse: FDA Adcomm Backing For Novavax's COVID-19 Shot, New Data On Moderna's Omicron Vaccine, DBV Tech's Encouraging Peanut Allergy Trial Data ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Early Data Shows BioNTech's Personalized Therapy Safe In Pancreatic Cancer Patients ↗
 
Via Benzinga
News headline image
Diagnostic Companies Focus On Monkeypox Tests Following Outbreak; Experts Do Not Count It As Next COVID Yet ↗
Diagnostic companies aggressively developed tests for monkeypox as governments struggle to trace the world's first major viral infection outbreak beyond Africa, 
Via Benzinga
News headline image
FDA Approves Genentech’s Evrysdi (risdiplam) for Use in Babies Under Two Months With Spinal Muscular Atrophy (SMA)
From Genentech
Via Business Wire
News headline image
New Pivotal Data Demonstrate Clinical Benefit of Genentech’s Glofitamab, a Potential First-in-Class Bispecific Antibody for People With Aggressive Lymphoma
From Genentech
Via Business Wire
News headline image
One-Trick Pony Boan Biotech Files for Hong Kong IPO Into Tough Market ↗
Key Takeaways: Boan Biotechnology sells only one product so far and is facing stiff competition from other similar drugs Luye Pharma bought Boan in 2020 and is taking it public... 
Via Benzinga
News headline image
Data at the 2022 ASCO Annual Meeting Highlight Genentech’s Continued Commitment to Innovation in Oncology and Personalized Healthcare
From Genentech
Via Business Wire
News headline image
Seagen Posts Encouraging Data From Tucatinib Combo Trial In Colorectal Cancer ↗
 
Via Benzinga
News headline image
Teva Pharmaceutical Shares Real-World Data Of ProAir Digihaler In Asthma Patients ↗
 
Via Benzinga
News headline image
Current Report: Roche Holding ↗
Roche’s price per share was $39.75 as of Friday's market close. One year ago its price was $42.20. 
Via Talk Markets
News headline image
The OTC Markets' Most Active Securities Welcomes New Names And Experiences A Reshuffle In April ↗
Photo by Becca on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. First-quarter 2022 market... 
Via Benzinga
News headline image
Why Roche's Flop In Lung Cancer Hammered Arcus, Iteos And Others ↗
Roche isn't the only company working on an anti-TIGIT molecule. 
Via Investor's Business Daily
News headline image
The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Genentech's Tiragolumab/Tecentriq Fails On Progression Free Survival In PD-L1-High Metastatic Lung Cancer ↗
Genentech, a unit of Roche Holdings AG (OTC: RHHBY), announced results from its Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab in PD-L1-high locally advanced or metastatic non-small cell lung... 
Via Benzinga
News headline image
Genentech Reports Interim Results for Phase III SKYSCRAPER-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer
From Genentech
Via Business Wire
News headline image
Market Selloff ↗
In a U.S. market selloff, the strong performance of mostly foreign issues was impressive. 
Via Talk Markets
News headline image
Roche Releases More Evrysdi Data For Very Young Infants With SMA ↗
 
Via Benzinga
News headline image
New Three-Year Data for Genentech’s Evrysdi (risdiplam) Show Long-Term Improvements in Survival and Motor Milestones in Babies With Type 1 Spinal Muscular Atrophy (SMA)
From Genentech
Via Business Wire
News headline image
Novartis Posts Higher Q1 Earnings, Sales On Strong Sandoz, Entresto; Backs 2022 Outlook ↗
 
Via Benzinga
News headline image
Roche's CEO Warns Russia-Ukraine War Causing Problems For Multiple Sclerosis Trials ↗
The development of Roche Holdings AG's (OTC: RHHBY) multiple sclerosis candidate fenebrutinib is negatively impacted by Russia's ongoing invasion of Ukraine. 
Via Benzinga
News headline image
COVID-19 Tests Boost Roche's Q1 Sales, Reaffirms FY22 Outlook ↗
 
Via Benzinga
News headline image
EMA' Advisory Committee Recommends Approval For Roche's Two Cancer Drugs ↗
 
Via Benzinga
News headline image
7 Potential Biotech Stocks Buyout Targets in 2022 ↗
Drug development is a cumbersome process and M&A is a win-win proposition for both the acquirer and the target company. 
Via InvestorPlace
News headline image
FDA Warns Against Relying On Screening Tests For Prenatal Diagnosis ↗
The U.S. FDA is warning that noninvasive prenatal screening (NIPS) tests may provide false results, such as stating a fetus may have a genetic abnormality when the fetus was... 
Via Benzinga
News headline image
4 Undervalued Biotech Stocks to Add to Your Buy List ↗
These biotech stocks have seen their valuations tumble in the year-to-date sell-off. But they have the wherewithal to bounce big and generate decent, market-beating returns. 
Via InvestorPlace
News headline image
Lessons For Elon Musk: 5 Notorious Failed Hostile Takeovers ↗
Let’s pause to consider earlier attempts at hostile takeovers by well-respected and well-financed entities and individuals that — to ransack some Musk-worthy clichés — took off like a rocket ship but... 
Via Talk Markets
News headline image
Lessons For Elon Musk: 5 Notorious Failed Hostile Takeovers ↗
As any student of industry knows, Elon Musk is hardly the first person to attempt a hostile takeover. 
Via Benzinga
News headline image
FDA Extends Review Period For Regeneron's COVID-19 Antibody Therapy ↗
 
Via Benzinga
News headline image
Volume Springs Back Into The OTC Markets In March – Take A Look At Some Of The Top Movers ↗
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Trading volume appears to be moving back to OTC Markets... 
Via Benzinga
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
34 35 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.